Peter Mueller
Executive Vice President, Drug Innovation and Realization, and Chief Scientific Officer
Dr. Mueller currently serves as our Executive Vice President, Drug Innovation and Realization, and Chief Scientific Officer, a position he has held since February 2006. He is responsible for all Research and Drug Discovery operations, as well as Pharmaceutical Development (CMC), Quality Assurance and Control and Pharmaceutical Operations for all Vertex’s product candidates.
Prior to joining Vertex, Dr. Mueller was the Senior Vice President, Research and Development, of Boehringer Ingelheim Pharmaceuticals, Inc., with responsibility for the development of all drug candidates in the company’s worldwide portfolio in North America. In the US he also led research programs in the areas of immunology, inflammatory cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, Dr. Mueller oversaw the discovery, development and approval of numerous development candidates and held several positions in basic research, medicinal chemistry and management. Dr. Mueller received both an undergraduate degree and a Ph.D. in chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretic Organic Chemistry. He completed fellowships in quantum pharmacology at Oxford University and in biophysics at Rochester University.
Peter Mueller
Network Innovator
“One of the key questions facing us in research and development is; how do we most effectively and efficiently leverage and boost our innovative capacity, increase our productivity and enhance our competitive advantage?”
“We think a bigger part of the answer lies in building Vertex-driven, global and interdisciplinary networks of innovation—hand-picking external frontier scientists, institutions and/or companies that we believe can leverage and augment our internal expertise, and collaborating with them in a fundamentally new way. We envision these as not just one-to-one technology alliances, but true networks, that can collectively tackle a complex problem that would be impossible for any one of us to achieve by ourselves. The goal is to create an environment that is fun, constantly challenges the status quo and thereby not only fosters innovation but also drives productivity as well as research and development economy.”
“In my role at Vertex, I am focused on applying the network concept across our drug discovery and development programs, with a goal of ensuring a steady stream of novel, highest-quality drug candidates with disease transforming potential that can carry forward Vertex into an exciting and sustainable future.”